Free Cash Flow

Vermilion Energy boosts its dividend for the fifth straight year, a move backed by strong cash flow and a strategic focus on premium gas markets.

MISTRAS Group reported record Adjusted EBITDA for 2025, signaling a successful shift to profitability over pure growth, and plans major tech investments.

The energy services firm surpassed analyst expectations with strong revenue growth and a key acquisition, but warns of a challenging year ahead.

With a unique entry-blocking drug, Bioxytran targets COVID, flu, and RSV, moving toward a pivotal trial that could redefine antiviral treatment.

For millions with disabilities, a simple ride is a lifeline. One company is turning a logistical nightmare into a path to independence and essential care.

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

The water solutions giant unveiled ambitious new financial targets, aiming to capitalize on water scarcity and infrastructure needs while reassuring investors.

The miner renewed its bid to buy back 5% of its stock, but its history of low execution raises questions about its commitment to the major capital plan.

Predactiv launches a 'push button' lookalike modeling feature, enabling businesses to turn proprietary data into new revenue streams without heavy engineering.

At its 90th anniversary, the Ford Foundation appoints Jason W. Ingle, Henry Ford's great-great-grandson, signaling a new chapter blending legacy with impact investing.

Unifi launches Luxel, a new yarn blending linen's feel with performance tech and circular recycling, aiming to redefine sustainable fashion and home goods.

Techtronic Industries reports record profits driven by its MILWAUKEE and RYOBI brands, even as it navigates tariffs and restructures its struggling floorcare unit.

Once a failing firm, Aurelion Inc. bet its future on tokenized gold. The gamble paid off with a profitable quarter, but regulatory risks loom large.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

With promising clinical data for its heart disease treatments, Lexeo Therapeutics aims to capture investor attention at the upcoming Leerink conference.

The digital asset giant is delisting from Toronto to streamline costs, a move that reshapes its buyback plan and how Canadian investors trade its stock.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

A major renewal with a 30M-client bank highlights the industry's shift to biometrics, boosting BIO-key's finances and solidifying its market niche.

Post-listing, the Swiss HealthTech firm pushes for US market expansion and European reimbursement, streamlining its focus on AI-powered brain health.

Hong Kong's Ming Shing Group replaces its CFO and CAO, bringing in a new financial architect as its stock tumbles and it navigates a risky Bitcoin bet.